PTC Therapeutics (PTCT) CFO sells shares in tax-cover trade post RSU vest

Rhea-AI Filing Summary

PTC Therapeutics’ chief financial officer, Pierre Gravier, reported an automatic sale of company stock tied to RSU vesting. On 01/06/2026, he sold 2,139 shares of PTC Therapeutics common stock at a price of $76.95 per share. The filing states these shares were sold pursuant to an irrevocable “sell to cover” election entered into when he accepted the grant, in order to satisfy tax withholding obligations on the vesting of 5,625 restricted stock units (RSUs) from a January 3, 2025 grant of 22,500 RSUs. Following this tax-related sale, he beneficially owned 90,310 shares of PTC Therapeutics common stock directly.

Insights

Corporate governance analyst

CFO’s reported stock sale is a routine tax-withholding transaction.

The filing shows PTC Therapeutics’ CFO, Pierre Gravier, reported selling 2,139 shares of common stock on January 6, 2026 at $76.95 per share. The accompanying note explains this was an automatic sale under an irrevocable “sell to cover” election tied to restricted stock unit (RSU) vesting, rather than a discretionary open-market sale.

The sale covered tax withholding on the vesting of 5,625 RSUs from a larger January 3, 2025 grant of 22,500 RSUs, which is a common mechanism for handling payroll taxes on equity awards. After this transaction, the CFO still directly held 90,310 shares, indicating continued equity exposure. Based on the disclosed facts, this appears to be standard compensation-related activity rather than a thesis-changing insider move.

Insider Trade Summary

Net Seller: 2,139 shares ($164,596)

Net Sell 1 txn

Insider Gravier Pierre

Role CHIEF FINANCIAL OFFICER

Sold 2,139 shs ($165K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,139	$76.95	$165K

Holdings After Transaction: Common Stock — 90,310 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gravier Pierre

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S		2,139(1)	D	$76.95	90,310	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,625 RSUs from a January 3, 2025 grant of 22,500 RSUs

	/s/ Avraham S. Adler, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) report in this Form 4?

The chief financial officer of PTC Therapeutics, Pierre Gravier, reported selling 2,139 shares of the company’s common stock on January 6, 2026 at a price of $76.95 per share.

Why did the PTC Therapeutics CFO sell 2,139 shares of PTCT stock?

The filing explains the 2,139 shares were automatically sold under an irrevocable “sell to cover” election made when he accepted the grant, to satisfy tax withholding obligations on the vesting of 5,625 RSUs from a January 3, 2025 grant.

How many PTC Therapeutics shares does the CFO hold after this transaction?

After the reported sale, the PTC Therapeutics CFO beneficially owned 90,310 shares of the company’s common stock, held in direct ownership.

What equity award was associated with the tax-related sale for PTC Therapeutics’ CFO?

The tax-related sale was tied to the vesting of 5,625 restricted stock units (RSUs), which are part of a larger 22,500 RSU grant dated January 3, 2025.

Is the reported PTC Therapeutics CFO stock sale a discretionary trade?

No. According to the explanation in the filing, the shares were sold automatically under an irrevocable “sell to cover” arrangement to pay withholding taxes on RSU vesting, rather than as a discretionary open-market trade.

What role does the reporting person hold at PTC Therapeutics (PTCT)?

The reporting person, Pierre Gravier, is identified as an officer of PTC Therapeutics, serving as the company’s Chief Financial Officer.